title: Neoadjuvant chemotherapy for intermediate/high-grade soft tissue sarcomas: five-year results with epirubicin and ifosfamide.
abstract: BACKGROUND
  Neoadjuvant chemotherapy for intermediate/high-grade soft tissue sarcomas (STS) may provide some advantages for facilitating the surgical resection of the tumor and for disease control. However its role as induction therapy before surgery should still be proved.
  
  
  METHODS
  Twenty-one patients with intermediate/high-grade STS and tumor size > or = 5 cm were consecutively treated from 1997 to 2001 with neoadjuvant chemotherapy based on epirubicin 60 mg/m2/day on days 1 and 2 and ifosfamide 1.8 gr/m2/day on days 1 through 5 every three weeks. Evaluation of objective tumor response and toxicity were carried out according to WHO criteria.
  
  
  RESULTS
  Nine partial responses were documented; stable disease in 11 patients, progressive disease in one patient. Apart from nine cases of grade 4 neutropenia, the treatment was generally well-tolerated. Twelve patients underwent conservative and limb salvage surgery.
  
  
  CONCLUSIONS
  This therapeutic approach seems to be effective in facilitating surgery. Neutropenia was the most significant toxicity but it was preventable or medically treatable with G-CSF support.
authors.affiliation: Department of Medical Oncology B, Division of Medical Oncology B, National Cancer Institute, G. Pascale, Via M. Semmola, 80131, Naples, Italy. ale.otto@libero.it
authors.forename: A
authors.initials: A
authors.lastname: Ottaiano
authors.forename: A
authors.initials: A
authors.lastname: De Chiara
authors.forename: F
authors.initials: F
authors.lastname: Fazioli
authors.forename: V
authors.initials: V
authors.lastname: De Rosa
authors.forename: V
authors.initials: V
authors.lastname: Ravo
authors.forename: V
authors.initials: V
authors.lastname: Boccia
authors.forename: G
authors.initials: G
authors.lastname: Botti
authors.forename: A
authors.initials: A
authors.lastname: Petrillo
authors.forename: F
authors.initials: F
authors.lastname: Fiore
authors.forename: S
authors.initials: S
authors.lastname: Mori
authors.forename: N
authors.initials: N
authors.lastname: Mozzillo
authors.forename: V R
authors.initials: VR
authors.lastname: Iaffaioli
authors.forename: G
authors.initials: G
authors.lastname: Apice
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018572:Disease-Free Survival; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D015251:Epirubicin; D007069:Ifosfamide